Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or $0.21 per share, for the third quarter ended 30 September 2011.
Subscribe to our email newsletter
Loss from operations for third quarter of 2012 was $9.07m compared to loss from operations of $6.47m for the third quarter of 2011.
The company reported a net loss attributable to common stockholders of $21.99m, or $0.23 per share, for the nine months ended 30 September 2012 compared to a net income attributable to common stockholders of $13.14m, or $0.15 per share, for the nine months ended 30 September 2011.
Loss from operations of $20.96m was reported for the first nine months of 2012 compared to loss from operations of $15.06m for the first nine months of 2011.
Navidea president and CEO Dr. Mark Pykett said the company believes that the FDA review process will involve re-evaluation of only a small portion of the NDA and that the focused information the company has provided will support a potentially expeditious review.
"Our clear priority continues to be Lymphoseek approval and launch in the U.S. We are committed to providing this novel radiopharmaceutical for use in critical diagnostic procedures for medical professionals, cancer patients and their families," Dr. Pykett added.